Skip to main content
Clinical Trials/NCT00874809
NCT00874809CompletedNot Applicable

A Pilot Study to Explore Basal Insulin Dosing Requirements in Patients With Type 2 Diabetes Treated With Insulin Pump Therapy

Diabetes Care Center1 site in 1 country30 target enrollmentStarted: March 1, 2009Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
30
Locations
1
Primary Endpoint
What are the mean number of changes in the basal infusion rate(change is defined as any alternation in the basal rate >0.1 U/hr) and what are the mean differences and mean duration (hrs) of these changes.

Study Overview

Brief Summary

The main purpose of this study is to determine the number of daily basal insulin rate changes that are needed to achieve short-term near normal glucose control in insulin pump patients with type 2 diabetes

Detailed Description

Subjects will be taught CHO counting after which they will be introduced to an insulin pump. They will wear the insulin pump for three weeks to adjust to the pump and its functions. Then the subject will wear a Continuous Glucose Monitoring System to determine rate changes needed to achieve short-term near normal glucose control. The primary endpoint is what are the mean number of changes in the basal infusion rate and what are the mean differences and mean duration of these changes. The secondary endpoint is what mathematical formulas describe the relationship between the dosing factors and do they significantly differ from those previously established by King and Armstrong.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Type 2 diabetes > 3month duration
  • •Hb A1C <12%
  • •On any hypoglycemic therapy including insulin for 5 patients and 5 patients naive to insulin and failing oral treatment
  • •Normal creatine
  • •Negative for GAD antibodies
  • •SMBG >4/d and willing/able to comply with study requirements
  • •Demonstrated adherence to visits and instructions.

Exclusion Criteria

  • •Severe hypoglycemic during the last month
  • •Severe cardiac, pulmonary or cerebral disease
  • •Demonstrated non compliance with clinical recommendations
  • •Pregnancy, nursing or women who could potentially become pregnant
  • •Presence of physical, psychological or cognitive impairments that would interfere with adherence to an intensive insulin therapy program or compliance with dietary, diary keeping or maintenance of CGM sensor or pump

Arms & Interventions

Insulin Treatment

Other

There is only one arm for this study using lispro insulin administered by insulin pump.

Intervention: CGMS with an insulin pump using rapid acting insulin (Device)

Outcomes

Primary Outcomes

What are the mean number of changes in the basal infusion rate(change is defined as any alternation in the basal rate >0.1 U/hr) and what are the mean differences and mean duration (hrs) of these changes.

Time Frame: week six of study

Secondary Outcomes

  • What mathematical formulas describe the relationship between the dosing factors and do they significantly differ from those previously established by King and Armstrong(week 6 of study)

Investigators

Sponsor Class
Industry
Responsible Party
Principal Investigator
Principal Investigator

Allen B. King, MD

Principal Investigator

Diabetes Care Center

Study Sites (1)

Loading locations...

Similar Trials